AIMT - AcelRx Acquiring Tetraphase And Other News: The Good Bad And Ugly Of Biopharma
AcelRx Pharmaceuticals Reports Q4 Results, to Acquire Tetraphase Pharmaceuticals
AcelRx (ACRX) reported its fourth quarter and full-year results while also announcing its plan to acquire Tetraphase Pharmaceuticals (TTPH). The company ended the year with $66.1 million in cash, cash equivalents, and short-term investments. For the fourth quarter, AcelRx reported its net revenue at $0.5 million while its full-year revenue stood at $2.3 million. Its combined research and development expenses and selling, general, and administrative expenses for the fourth quarter were reported at $13.8 million, up from $10.4 million it had reported for the